Ginsenoside 20(s)-Rh2 as potent natural histone deacetylase inhibitors suppressing the growth of human leukemia cells

Chemico-Biological Interactions

Volumn 242, Issue , 2015, Pages 227-234

  Liu, Ze Hong ^a   Li, Jing ^a   Xia, Jing ^b   Jiang, Rong ^a   Zuo, Guo Wei ^a   Li, Xiao Peng ^a   Chen, Yi ^a   Xiong, Wei ^a   Chen, Di Long ^a  

^a CHONGQING MEDICAL UNIVERSITY   (China)

^b Department of Human Anatomy Chongqing Medical and Health School ^*  (China)

Author keywords

Apoptotic; Ginsenoside; HDAC; Leukemia

Indexed keywords

CASPASE 3; CYCLIN D1; GINSENOSIDE RH 2; HISTONE ACETYLTRANSFERASE; HISTONE DEACETYLASE; HISTONE DEACETYLASE 1; HISTONE DEACETYLASE 2; HISTONE DEACETYLASE 6; HISTONE H3; MITOGEN ACTIVATED PROTEIN KINASE; MITOGEN ACTIVATED PROTEIN KINASE P38; PROTEIN BAX; PROTEIN BCL 2; ANTINEOPLASTIC AGENT; GINSENOSIDE; HISTONE; HISTONE DEACETYLASE INHIBITOR;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER INHIBITION; CELL CYCLE REGULATION; CELL PROLIFERATION; CELL VIABILITY; CONTROLLED STUDY; DRUG CYTOTOXICITY; DRUG MECHANISM; ENZYME ACTIVITY; ENZYME INHIBITION; ENZYME PHOSPHORYLATION; G1 PHASE CELL CYCLE CHECKPOINT; HEMATOPOIETIC STEM CELL; HISTONE ACETYLATION; HUMAN; HUMAN CELL; IC50; IMMUNOBLOTTING; IN VITRO STUDY; IN VIVO STUDY; LEUKEMIA CELL LINE; MOLECULAR DYNAMICS; MOUSE; NONHUMAN; PROTEIN CLEAVAGE; PROTEIN EXPRESSION; TUMOR GROWTH; TUMOR VOLUME; TUMOR XENOGRAFT; ACETYLATION; ANIMAL; CELL CYCLE; CELL SURVIVAL; CYTOLOGY; DRUG EFFECTS; GENE EXPRESSION REGULATION; K562 CELL LINE; LEUKEMIA; MALE; MESENCHYMAL STROMA CELL; METABOLISM; PATHOLOGY; SIGNAL TRANSDUCTION;

ACETYLATION; ANIMALS; ANTINEOPLASTIC AGENTS; APOPTOSIS; CELL CYCLE; CELL PROLIFERATION; CELL SURVIVAL; GENE EXPRESSION REGULATION, NEOPLASTIC; GINSENOSIDES; HISTONE ACETYLTRANSFERASES; HISTONE DEACETYLASE INHIBITORS; HISTONE DEACETYLASES; HISTONES; HUMANS; K562 CELLS; LEUKEMIA; MALE; MAP KINASE SIGNALING SYSTEM; MESENCHYMAL STROMAL CELLS; MICE;

EID: 84944874407     PISSN: 00092797     EISSN: 18727786     Source Type: Journal    
DOI: 10.1016/j.cbi.2015.10.014     Document Type: Article

References (34)

1. J. Schonheit, A. Leutz, and F. Rosenbauer Chromatin dynamics during differentiation of myeloid cells J. Mol. Biol. 427 3 2015 670 687
2. R.L. Neppl, and D.Z. Wang The myriad essential roles of microRNAs in cardiovascular homeostasis and disease Genes Dis. 1 1 2014 18 39
3. T. Schoofs, W.E. Berdel, and C. Muller-Tidow Origins of aberrant DNA methylation in acute myeloid leukemia Leukemia 28 1 2014 1 14
4. J. Chen, O. Odenike, and J.D. Rowley Leukaemogenesis: more than mutant genes Nat. Rev. Cancer 10 1 2010 23 36
5. Y. Zhang, and H. Moriguchi Chromatin remodeling system, cancer stem-like attractors, and cellular reprogramming Cell Mol. Life Sci. 68 21 2011 3557 3571
6. E. Smith, and A. Shilatifard The chromatin signaling pathway: diverse mechanisms of recruitment of histone-modifying enzymes and varied biological outcomes Mol. Cell 40 5 2010 689 701
7. A.J. Ruthenburg, and et al. Multivalent engagement of chromatin modifications by linked binding modules Nat. Rev. Mol. Cell Biol. 8 12 2007 983 994
8. A.L. Clayton, C.A. Hazzalin, and L.C. Mahadevan Enhanced histone acetylation and transcription: a dynamic perspective Mol. Cell 23 3 2006 289 296
9. V. Sapountzi, and J. Cote MYST-family histone acetyltransferases: beyond chromatin Cell Mol. Life Sci. 68 7 2011 1147 1156
10. B.J. Kim Involvement of melastatin type transient receptor potential 7 channels in ginsenoside Rd-induced apoptosis in gastric and breast cancer cells J. Ginseng Res. 37 2 2013 201 209
11. N. Wu, and et al. Ginsenoside Rh2 inhibits glioma cell proliferation by targeting microRNA-128 Acta Pharmacol. Sin. 32 3 2011 345 353
12. D.G. Popovich, and D.D. Kitts Ginsenosides 20(S)-protopanaxadiol and Rh2 reduce cell proliferation and increase sub-G1 cells in two cultured intestinal cell lines, Int-407 and Caco-2 Can. J. Physiol. Pharmacol. 82 3 2004 183 190
13. T. Xia, and et al. 20S-Ginsenoside Rh2 induces apoptosis in human Leukaemia Reh cells through mitochondrial signaling pathways Biol. Pharm. Bull. 37 2 2014 248 254
14. A.M. Popov, and et al. The antimetastatic and immunomodulating activities of ginseng minor glycosides Dokl. Biochem. Biophys. 380 2001 309 312
15. S. Fulzele, and et al. Sodium-dependent vitamin C transporter SVCT2: expression and function in bone marrow stromal cells and in osteogenesis Stem Cell Res. 10 1 2013 36 47
16. J. Shi, and et al. Pharmacokinetic interactions between 20(S)-ginsenoside Rh2 and the HIV protease inhibitor ritonavir in vitro and in vivo Acta Pharmacol. Sin. 34 10 2013 1349 1358
17. L.S. Steelman, and et al. Roles of the Ras/Raf/MEK/ERK pathway in leukemia therapy Leukemia 25 7 2011 1080 1094
18. E. Shishtar, and et al. The effect of ginseng (the genus panax) on glycemic control: a systematic review and meta-analysis of randomized controlled clinical trials PLoS One 9 9 2014 e107391
19. D.D. Kitts, D.G. Popovich, and C. Hu Characterizing the mechanism for ginsenoside-induced cytotoxicity in cultured leukemia (THP-1) cells Can. J. Physiol. Pharmacol. 85 11 2007 1173 1183
20. I.F. Dunn, and P.M. Black The neurosurgeon as local oncologist: cellular and molecular neurosurgery in malignant glioma therapy Neurosurgery 52 6 2003 1411 1422 discussion 1422-4
21. X. Qu, and et al. Pseudo-G-Rh2 induces mitochondrial-mediated apoptosis in SGC-7901 human gastric cancer cells Oncol. Rep. 26 6 2011 1441 1446
22. C. Zhang, H. Yu, and J. Hou Effects of 20 (S) -ginsenoside Rh2 and 20 (R) -ginsenoside Rh2 on proliferation and apoptosis of human lung adenocarcinoma A549 cells Zhongguo Zhong Yao Za Zhi 36 12 2011 1670 1674
23. B. Barneda-Zahonero, and M. Parra Histone deacetylases and cancer Mol. Oncol. 6 6 2012 579 589
24. S. Saji, and et al. Significance of HDAC6 regulation via estrogen signaling for cell motility and prognosis in estrogen receptor-positive breast cancer Oncogene 24 28 2005 4531 4539
25. J.S. Carew, F.J. Giles, and S.T. Nawrocki Histone deacetylase inhibitors: mechanisms of cell death and promise in combination cancer therapy Cancer Lett. 269 1 2008 7 17
26. C. Choudhary, and et al. Lysine acetylation targets protein complexes and co-regulates major cellular functions Science 325 5942 2009 834 840
27. M. Rodriguez-Paredes, and M. Esteller Cancer epigenetics reaches mainstream oncology Nat. Med. 17 3 2011 330 339
28. Christina M. Grozinger, C.A.H., and Stuart L. Schreiber∗ Three proteins define a class of human histone deacetylases related to yeast Hda1p Proc. Natl. Acad. Sci. 96 1999 4868 4873
29. P. Gallinari, and et al. HDACs, histone deacetylation and gene transcription: from molecular biology to cancer therapeutics Cell Res. 17 3 2007 195 211
30. B. Hackanson, and et al. HDAC6 as a target for antileukemic drugs in acute myeloid leukemia Leuk. Res. 36 8 2012 1055 1062
31. X. Mao, and et al. The tricyclic antidepressant amitriptyline inhibits D-cyclin transactivation and induces myeloma cell apoptosis by inhibiting histone deacetylases: in vitro and in silico evidence Mol. Pharmacol. 79 4 2011 672 680
32. S. Inoue, and et al. Inhibition of histone deacetylase class I but not class II is critical for the sensitization of leukemic cells to tumor necrosis factor-related apoptosis-inducing ligand-induced apoptosis Cancer Res. 66 13 2006 6785 6792
33. E.D. Robertson, and et al. ARNT controls the expression of epidermal differentiation genes through HDAC- and EGFR-dependent pathways J. Cell Sci. 125 Pt 14 2012 3320 3332
34. A. Rosati, and et al. Quassinoids can induce mitochondrial membrane depolarisation and caspase 3 activation in human cells Cell Death Differ. 11 Suppl. 2 2004 S216 S218